Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative PRRT vs. surgery alone in metastatic PanNET
NCT05610826Phase 2Withdrawn
- Sponsor
- University of Chicago
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177 dotatate in Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by University of Chicago. Primary endpoint: Progression-Free Survival at 2 years. Planned start Mar 2023; status: withdrawn.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT05610826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610826.